The incidence and age-adjusted mortality of colorectal cancer (CRC) has drastically
increased in the past 2 decades in Taiwan. Fortunately, chemotherapy for metastatic CRC …

Background Oxaliplatin is an integral component of colorectal cancer treatment, but its use is
limited by neurotoxicity. The Combined Oxaliplatin Neurotoxicity Prevention Trial …

Background Oxaliplatin is effective in adjuvant and first-line colorectal cancer chemotherapy.
Oxaliplatin-induced severe chronic neurotoxicity is the main dose-limiting adverse event. No …

Oxaliplatin-based chemotherapy is an effective first-line treatment option for patients with
metastatic colorectal cancer (mCRC), which, in combination with targeted therapies and a …

Background: Colorectal cancer (CRC) is a public health problem and the world's leading
cancer killer. It is a disease with high incidence and mortality. Although chemotherapy has …

4067 Background: N9741 randomized 1691 patients (pts) to seven 5FU, Ox and Iri
containing regimens for MCRC. After 20.4 months median follow-up, FOLFOX and IROX …

Objectives: To evaluate three technologies for the management of advanced colorectal
cancer:(1) first-line irinotecan combination [with 5-fluorouracil (5-FU)] or second-line …

Introduction Chemotherapy-induced thrombocytopenia (CIT) contributes to treatment dose
delay and/or modification, often resulting in poorer survival and disease progression. We …

Colorectal cancer (CRC) therapy using conventional chemotherapeutics represents a
considerable burden for the patient's organism because of high toxicity while the response is …

Background: First-line chemotherapeutic treatment of colorectal cancer (CRC) typically
comprises oral (capecitabine) or intravenous 5-fluorouracil (5-FU) plus leucovorin (LV), in …